NCT05471492View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 30, 2023

Primary Completion Date

August 15, 2026

Study Completion Date

August 15, 2026

Conditions
Crohn Disease
Interventions
DRUG

Investigational Product

PF-06480605 150 mg

DRUG

Placebo

Placebo

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Telavant, Inc.

INDUSTRY

NCT05471492 - Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease | Biotech Hunter | Biotech Hunter